Gary Hogan wants you to know that while the Elks’ light may be temporarily dimmed due to the sale and demolition of their ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.